PReCedeNT trial: Phase III randomized-controlled trial of Lutetium − 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Saved in:
| Title: | PReCedeNT trial: Phase III randomized-controlled trial of Lutetium − 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) |
|---|---|
| Authors: | Puranik, Ameya D.1 (AUTHOR) ameya2812@gmail.com, Dev, Indraja D.1 (AUTHOR), Yadav, Sushil1 (AUTHOR), Rangarajan, Venkatesh1 (AUTHOR), Agrawal, Archi1 (AUTHOR), Basu, Sandip2 (AUTHOR), Chaudhari, Vikram A.3 (AUTHOR), Ramaswamy, Anant4 (AUTHOR), Ostwal, Vikas4 (AUTHOR), Bhandare, Manish S.3 (AUTHOR), Shrikhande, Shailesh V.3 (AUTHOR), Parghane, Rahul V.2 (AUTHOR), Bhargava, Prabhat4 (AUTHOR), Bal, Munita M.5 (AUTHOR), Yadav, Subhash5 (AUTHOR), Patkar, Shraddha3 (AUTHOR), Goel, Mahesh3 (AUTHOR), Purandare, Nilendu C.1 (AUTHOR), Shah, Sneha1 (AUTHOR), Choudhury, Sayak1 (AUTHOR) |
| Source: | BMC Cancer. 10/28/2025, Vol. 25 Issue 1, p1-8. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 14712407 |
|---|---|
| DOI: | 10.1186/s12885-025-15111-x |
